Navigating Patient Access Challenges When Bringing Your CGT Product To Market

Bringing a cell or gene therapy (CGT) product to market is a monumental achievement—but commercialization success hinges on overcoming patient access barriers. These advanced therapies offer life-changing potential, yet many patients struggle to receive treatment due to awareness gaps, logistical hurdles, and financial constraints. A well-structured commercialization strategy must prioritize patient access to ensure CGTs reach those who need them most.

Manufacturers must take a proactive approach by enhancing provider education, streamlining patient support services, and improving coordination among stakeholders. Addressing these challenges requires strategies such as increasing awareness of financial and logistical assistance, optimizing patient journey visibility, and expanding treatment site accessibility. Additionally, implementing integrated patient support programs can help mitigate delays, ensuring continuity from diagnosis to therapy administration.

How can your organization build a seamless, patient-centric commercialization strategy? This article provides expert insights and actionable recommendations to help you navigate the complexities of CGT patient access. Read on to discover how to optimize your approach, reduce barriers, and deliver on the full potential of your therapy.